Galunisertib is supposed to suppress the activation of SMAD2 in neuroblastomas and activate NK cells, restore NK cytotoxic activity, and increase the efficacy of dinutuximab with activated NK cells against neuroblastoma tumors [286]. Here, SMAD2 is linked to neuroblastoma.